David Moller has joined Poxel as its chief scientific officer, the same position he held most recently at Sigilon Therapeutics. Moller’s experience also includes research and development roles at Eli Lilly (NYSE: [[ticker:LLY]]) and Merck (NYSE: [[ticker:MRK]]). Lyon, France-based Poxel is developing treatments for metabolic diseases, including type 2 diabetes and nonalcoholic steatohepatitis. Moller will be based in Poxel’s Boston office.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
